報價延遲最少15分鐘:2025/11/15 10:07 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
152.37 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.02/1.70
|
|
企業價值
9.15B
|
| 資產負債 |
|
每股賬面淨值
37.01
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
29.36M
|
|
每股收益
11.90
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/15 10:07 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
